Role of angiotensin II in diabetic nephropathy

Seminars in Nephrology

Volumn 17, Issue 5, 1997, Pages 441-447

  Kennefick, Thomas M ^a   Anderson, Sharon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

DIABETES MELLITUS; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; DRUG EFFECT; GENOTYPE; HUMAN; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENALAPRIL; HEMODYNAMIC PROCESSES; PLASMA VOLUME; RATS; RENIN-ANGIOTENSIN SYSTEM;

EID: 0030931455     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Zatz R, Dunn BR, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
2. Andersen S, Rennke HG, Garcia DL, et al: Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Int 36:526-536, 1989
3. Anderson S, Rennke HG, Brenner BM: Nifedipine vs. fosinopril in uninephrectomized diabetic rats. Kidney Int 41:891-897, 1992
4. Fabris B, Jackson B, Johnston CI: Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 17:497-503, 1991
5. Cooper ME, Alien TJ, O'Brien RC, et al: Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. Diabetes 39:1575-1579, 1990
6. Gaber L, Walton C, Brown S, et al: Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 46:161-169, 1994
7. Anderson S: Antihypertensive therapy in experimental diabetes. J Am Soc Nephrol 3:S86-S96, 1992
8. Perico N, Amuchastegui SC, Colosio V, et al: Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomenilar injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5:1139-1146, 1994
9. Anderson S, Jung FF, Ingelfinger JR: Renin-angiotensin system in diabetic rats: Functional, immunohistochemical, and molecular biologic correlations. Am J Physiol 265:F477-F486, 1993
10. Remuzzi A, Fassi A, Sangalli F, et al: Effect ofbenazapril and valsartan on glomerular injury in experimental diabetes in MWF/Ztm rats. J Am Soc Nephrol 7:1877,1996 (abstr)
11. Remuzzi A, Perico N, Amuchastegui CS, et al: Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 4:40-49, 1993
12. Okamoto K, Kashihar N, Sugiyama H, et al: Suppression of glomerular and renal hypertrophy in diabetes induced in angiotensin II Type la receptor-deficient mice. J Am Soc Nephrol 7:1876, 1996 (abstr)
13. Kasiske BL, Kalil RSN, Ma JZ, et al: Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138,1993
14. Böhlen L, de Courten M, Weidmann P: Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 7:84S-92S, 1994
15. Mathiesen ER, Hommel E, Giese J, et al: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. Br Med J 303:81-87, 1991
16. Viberti G, Mogensen CE, Groop LC, et al: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271:275-279, 1994
17. Ravid M, Lang R, Rachmani R, et al: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: A 7-year follow-up study. Ann Intern Med 156:286-289, 1996
18. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
19. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 45:861-867,1994
20. Weidmann P, Ferrari P: Central role of sodium in hypertension in diabetic subjects. Diabetes Care 13:220-232, 1991
21. Vora JP, Oyama TT, Thompson MM, Anderson S: Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes. Diabetes 46:107-112, 1997
22. Kennefick TM, Oyama TT, Thompson MM, et al: Enhanced renal sensitivity to angiotensin actions in diabetes mellitus in the rat. Am J Physiol 271:F595-F602, 1996
23. Vallon V, Mead LM, Blantz RC: Renal hemodynamics and plasma and kidney angiotensin II in estalished diabetes mellitus in rats: effects of sodium and salt restriction. J Am Soc Nephrol 5:1761-1767, 1995
24. Baylis C, Engels K, Hymel A, et al: Age dependent alterations in the metabolic clearance rate of angiotensin II in the rat. J Am Soc Nephrol 6:731, 1995 (abstr)
25. Gross V, Lippoldt A, Bohlender J, et al: The reninangiotensin system and renal function in transgenic (mRen2)27 rats. Exp Nephrol 4:20-26, 1996 (Suppl I)
26. Kohara K, Brosnihan KB, Chappell MC, et al: Angiotensin-(1-7): A member of circulating angiotensin peptides. Hypertension 17:131-138, 1991
27. Ferrario CM, Brosnihan KB, Diz DI, et al: Angiotensin-(1-7): A new hormone of the angiotensin system. Hypertension 18:111-126-111-133, 1991 (Suppl III)
28. Vernace MA, Herbert L, Mento PF, et al: Increased metabolic clearance of angiotensin II in diabetic rats: role of the kidneys. J Am Soc Nephrol 5:974, 1994 (abstr)
29. Thaiss F, Wolf G, Assad N, et al: Angiotensinase A gene expression and enzyme activity in isolated glomeruli of diabetic rats. Diabetologia 39:275-280, 1996
30. Dzau VJ: Multiple pathways of angiotensin production in the blood vessel wall: Evidence, possibilities and hypotheses. J Hypertension 7:933-936, 1989
31. Campbell DJ: Extrarenal renin and blood pressure regulation: An alternative viewpoint. Am J Hypertens 2:266-275, 1989
32. Luetscher JA: Microalbuminuria and increased plasma prorenin: Prevalence in diabetics followed up to four years. Arch Intern Med 148:937-941, 1988
33. Hsueh WA, Andersen PW: Prorenin and the reninangiotensin system in diabetic nephropathy. Semin Nephrol 13:573-580, 1993
34. Rosenberg ME, Smith LJ, Correa-Rotter R, et al: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 45:403-410, 1994
35. Burns KD, Homma T, Harris RC: The intrarenal reninangiotensin system. Semin Nephrol 13:13-30, 1993
36. Harris RC, Cheng H-F: The intrarenal renin-angiotensin system: A paracrine system for the local control of renal function separate from the systemic axis. Exp Nephrol 4:2-7, 1996 (Suppl 1)
37. Seikaly MG, Arant BS Jr, Seney FD Jr: Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. J Clin Invest 86:1352-1357, 1990
38. Navar LH, Lewis L, Hymel A, et al: Tubular fluid concentrations and kidney contents of angiotensin I and angiotensin II in anesthetized rats. J Am Soc Neprhol 5:1152-1158, 1194
39. Okwueze MI, Hymel AA, Van RC: Systemic and intrarenal angiotensin profiles during the onset of IDDM and glomerular hyperfiltration in BB/DP rats. J Am Soc Nephrol 4:800, 1993 (abstr)
40. Correa-Rotter R, Hosteller TH, Rosenberg ME: Renin and angiotensinogen gene expression in experimental diabeles mellilus. Kidney Inl 41:796-804, 1992
41. Jaffa AA, Chai KX, Chao J, el al: Effecls of diabeles and insulin on expression of kallikrein and renin genes in the kidney. Kidney Int 41:789-795, 1992
42. Cohen AJ, McCarthy DM, Rossetti RG: Renin secretion by the spontaneously diabetic rat. Diabeles 35:341-346, 1986
43. Ubeda M, Hernandez I, Fenoy F, et al: Vascular and adrenal reninlike activity in chronically diabetic rats. Hypertension 11:339-34, 1988
44. Everett AD, Scott J, Wilfong N, et al: Renin and angiotensinogen expression during evolution of diabetes. Hypertension 19:70-78, 1992
45. Kalinyak JE, Sechi LA, Griffin CA, et al: The reninangiotensin system in streptozotocin-induced diabetes mellitus in the rat. J Am Soc Nephrol 4:1337-1345, 1993
46. Cheng H-F, Burns KD, Harris RC: Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 46:1603-1610, 1994
47. Cheng H-F, Backer BN, Bums KD, et al: Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 95:2012-2019, 1995
48. Campbell DJ, Lawrence AC, Towrie A, et al: Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18:763-773, 1991
49. Price D, Porter L, De Oliveira J, et al: The paradox of the low-renin state: hormonal and renal responses to an angiotensin II antagonist, irbesartan, in diabetic nephropathy. J Am Soc Nephrol 7:1363, 1996 (abstr)
50. Hsueh WA: Effect of the renin-angiotensin system in the vascular disease of Type II diabetes mellitus. Am J Med 92:4B-13S-4B-19S, 1992 (Suppl 4B)
51. Wolf G, Ziyadeh FN: The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 29:153-163, 1997
52. Raij L, Keane WF: Glomerular mesangium: Its function and relationship to angiotensin II. Am J Med 79:24-36, 1985
53. Remuzzi G, Bertani T: Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38:384-394, 1990
54. Swartz SL, Williams GH, Hollenberg NK, et al: Increase in prostaglandins during converting enzyme inhibition. Clin Sei 59:133s-135s, 1980
55. Wilcox CS, Welch WJ, Snellen H: Thromboxane mediates renal hemodynamic response to infused angiotensin II. Kidney Int 40:1090-1097, 1991
56. Giachelli CM, Pichler R, Lombard! D, et al: Osteopontin expression in angiotensin-II induced tubulointerstitial nephritis. Kidney Int 45:515-524, 1994
57. Johnson RJ, Alpers CE, Yoshimura A, et al: Renal injury from angiotensin-II mediated hypertension. Hypertension 19:464-474, 1992
58. Tanaka R, Sugihara K, Tatematsu A, et al: Intemephron heterogeneity of growth factors and sclerosismodulation of platelet-derived growth factor by angiotensin II. Kidney Int 47:131-139, 1995
59. Naftilan AJ, Pratt RE, Dzau VJ: Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83:1419-1424, 1989
60. Itoh H, Mukoyama M, Pratt RE, et al: Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91:2268-2274, 1993
61. Nahman NS Jr, Rothe KL, Falkenhain ME, et al: Angiotensin II induction of fibronectin biosynthesis in cultured human mesangial cells: Association with CREB transcription factor activation. J Lab Clin Med 127:599-611, 1996
62. Kagami S, Border WA, Miller DE, et al: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β in rat glomerular mesangial cells. J Clin Invest 93:2431-2437, 1994
63. Vaughan DE, Lazos SA, Tong K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the reninangiotensin system and thrombosis. J Clin Invest 95:995-1001, 1995
64. Williams B, Baker AQ, Gallacher B, et al: Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25:913-917, 1995
65. Simon G, Abraham G, Altman S: Stimulation of vascular glycosaminoglycan synthesis by subpressor angiotensin II in rats. Hypertension 23:1-148-1-151, 1994 (Suppl I)
66. Moriyama T, Fujibayashi M, Fujiwara Y, et al: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 6:95-101, 1995
67. Hutchison FN, Cui X, Paul RV, et al: Increase in renal transforming growth factor β(TGF-β) in diabetes is angiotensin II dependent. J Am Soc Nephrol 7:1872, 1996 (abstr)
68. Leehey DJ, Singh R, Alavi N, et al: Glucose-induced inhibition of collagenase activity in mesangial cells is blocked by the angiotensin II antagonist losartan. J Am Soc Nephrol 7:1874, 1996 (abstr)
69. Yoshida H, Kon V, Ichikawa I: Polymorphisms of the renin-angiotensin system genes in progressive renal diseases. Kidney Int 50:732-744, 1996
70. Marre M, Bernadet P, Gallois Y, et al: Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic complications. Diabetes 43:384-388, 1994
71. Fogarty DG, Hughes AE, Neven NC, et al: Functional genetic markers of the renin-angiotensin system and the risk of diabetic nephropathy in insulin-dependent diabetes melluts. J Am Soc Nephrol 5:376, 1994 (abstr)
72. Schmidt S, Schone N, Giessel R, et al: Association of the ACE gene polymorphism and diabetic nephropathy. J Am Soc Nephrol 5:383, 1994 (abstr)
73. Dudley RK, Keavney B, Stratton IM, et al: U.K. Prospective Diabetes Study XV: Relationship of renin-angiotensin system gene polymorphisms with microalbuminuria in NIDDM. Kidney Int 48:1907-1911, 1995
74. Yoshida H, Kuriyama S, Atsumi Y, et al: Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50:657-664, 1996
75. Rossing K, Jacobsen P, Tamow L, et al: Role of angiotensin-converting enzyme (ACE) gene polymorphism and antiproteinuric effect of ACE inhibition in diabetic nephropathy. J Am Soc Nephrol 7:1364, 1996 (abstr)